anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the three double-blind, placebo-controlled trials in early Parkinson's disease, hallucinations were observed in 9% (35 of 388) of patients receiving MIRAPEX tablets, compared with 2.6% (6 of 235) of patients receiving placebo. In the four double-blind, placebo-controlled trials in advanced Parkinson's disease, where patients received MIRAPEX tablets and concomitant levodopa, hallucinations were observed in 16.5% (43 of 260) of patients receiving MIRAPEX tablets compared with 3.8% (10 of 264) of patients receiving placebo. Hallucinations were of sufficient severity to cause discontinuation of treatment in 3.1% of the early Parkinson's disease patients and 2.7% of the advanced Parkinson's disease patients compared with about 0.4% of placebo patients in both populations. 

Age appears to increase the risk of hallucinations attributable to pramipexole. In the early Parkinson's disease patients, the risk of hallucinations was 1.9 times greater than placebo in patients younger than 65 years and 6.8 times greater than placebo in patients older than 65 years. In the advanced Parkinson's disease patients, the risk of hallucinations was 3.5 times greater than placebo in patients younger than 65 years and 5.2 times greater than placebo in patients older than 65 years.

In the RLS clinical program, one pramipexole-treated patient (of 889) reported hallucinations; this patient discontinued treatment and the symptoms resolved.
Subjects will receive usual care through an outpatient substance use disorder treatment facility, will be provided with a wearable sensor and the RAE mobile application. Participants will be instructed to use the RAE app for a minimum of 30 days.
In the experimental group, saliva sample will be taken before chemotherapy, Personal Information Form, State Anxiety Scale and VAS pre-test questionnaires will be applied, pre-test questionnaires will be applied to measure vital signs, and then virtual reality glasses will be introduced to the patients and the duration will vary between 3-10 minutes for a total of 30 minutes. A saliva sample will be taken and a post-test will be applied, with virtual reality glasses, videos with music background, park, nature and seaside walks, underwater, museum trips, videos that the patient wants to watch and can change whenever they want. Each patient will be shown the same video.
Atherosclerosis (AS) poses a significant threat to human life and health. However, conventional antiatherogenic medications exhibit insufficient targeting precision and restricted therapeutic effectiveness. Moreover, during the progression of AS, macrophages undergo polarization toward the proinflammatory M1 phenotype and generate reactive oxygen species (ROS) to accelerate the occurrence of inflammatory storms, and ingest excess lipids to form foam cells by inhibiting cholesterol efflux. In our study, we developed a macrophage membrane-functionalized hollow mesoporous manganese dioxide nanomedicine (Col@HMnO2-MM). This nanomedicine has the ability to evade immune cell phagocytosis, enables prolonged circulation within the body, targets the inflammatory site of AS for effective drug release, and alleviates the inflammatory storm at the AS site by eliminating ROS. Furthermore, Col@HMnO2-MM has the ability to generate oxygen autonomously by breaking down surplus hydrogen peroxide generated at the inflammatory AS site, thereby reducing the hypoxic microenvironment of the plaque by downregulating hypoxia-inducible factor (HIF-1α), which in turn enhances cholesterol efflux to inhibit foam cell formation. In an APOE-/- mouse model, Col@HMnO2-MM significantly reduced inflammatory factor levels, lipid storage, and plaque formation without significant long-term toxicity. In summary, this synergistic treatment significantly improved the effectiveness of nanomedicine and may offer a novel strategy for precise AS therapy.
Youth in this study arm will receive 12 sessions of FFT (psychoeducation, communication skills training, and problem-solving skills training) with their parents and siblings. They and their parents will make regular mobile app ratings of mood, sleep, family functioning, stress, and perceived criticism. Children and parents will call into a voice-activated phone system and be asked to speak freely for 3-5 minutes about their health and family functioning. They will be guided through 12 lesson plans in which they practice skills such as active listening or identifying prodromal signs of episodes, paralleling what they are learning in sessions. The clinician will be able to set a weekly skill training assignment and observe the family's practice of the skill between sessions. They will adapt session content accordingly.
PURPOSE:To obtain a perfume composition for bath, having excellent dispersibility free from problems of deterioration and change of quality of perfume and corrosion of bathtub made of copper or stainless steel, containing a sulfur hot spring-like fragrance component composed of an alkylthiol and/or methylthioalkanol. CONSTITUTION:The objective substance containing 1-1,000ppm sulfur hot spring- like fragrance component composed of an alkylthiol and/or a methylthioalkanol. 3-Methyl-1-butanethiol may be cited as the alkylthiol and 3-methylthio-1-propanol as the methylthioalkanol. 3-Methylthio-1-propanol has a too offensive smell, diluted with a solvent such as dipropylene glycol into 0.1-3% solution and used. The sulfur hot spring-like fragrance component may be combined with various well-known perfume components (e.g. jasmine or rose) to produce a hot spring fragrance of new image.
COPD is a term for airflow restriction and growing shortness of breath caused by physiological deterioration. Elderly persons endure reduced respiratory function, stiffness in the joints and connective tissues of the rib cage, and increased thoracic Kyphosis as a result of COPD .breathlessness, cough, and sputum production are the most prevalent symptoms of COPD, while wheezing, chest tightness, and chest congestion are less common but nevertheless bothersome. The reported frequency, on the other hand, varies depending on the patient demographic and the severity of the disease. COPD is now the world's fourth greatest cause of mortality, but it is expected to rise to the third position by 2020.

Due to the obstruction and exhalation airflow is reduced, resulting in air trapping and hyperinflation. When the rate of minute ventilation or respiration is increased, for as during exercise, this becomes more apparent. Hyperinflation puts more strain on the respiratory muscles, forcing them to function in a restricted range of motion with a negative pressure/effort ratio, resulting in fatigue and increased shortness of breath. COPD patients avoid physical activity and adopt a more sedentary lifestyle than healthy older adults in order to prevent the distressing feeling of breathlessness. This, in turn, causes a vicious cycle of decreased exercise capacity, increased breathlessness during exercise, and more avoidance of exercise, and so on.

Active expiration, slow and deep breathing, pursed lips breathing, relaxation therapy, body positions such as forward leaning, inspiratory and expiratory muscle training, and diaphragmatic breathing are all examples of breathing techniques. Improvement of (regional) ventilation and gas exchange, decrease of dynamic hyperinflation, enhancement of respiratory muscle function, reduction of breathlessness, and improvement of exercise tolerance and quality of life are some of the goals of these procedures. Exercise capacity is impaired in COPD, both peak exercise capacity and functional exercise capacity. Besides lung hyperinflation and physical inactivity, ventilation-perfusion mismatch, hypoxemia, cardiovascular problems and muscular changes Reduced exercise capacity is a factor. One of the most important predictors of morbidity and mortality in COPD is functional exercise ability. and has a direct connection to everyday physical activities. Because rib cage mobility tends to be diminished with obstructive lung illness, PT appears to have a specific goal of rib cage joint mobility. Chest wall mobilization enhances chest wall mobility, lowers respiratory rate, raises tidal volume, improves ventilation gas exchange, reduces breathlessness, reduces work of breathing, and helps you relax. The rib cage mobilization is applied in three positions, supine ling, side lying and siding with arm abducted of the side to be mobilized.
PROBLEM TO BE SOLVED: To obtain the new subject product without requiring condensing the product so as to have a low water content, and excellent in preservation stability by allowing a candy to have a high water content and a high hardness. SOLUTION: The subject product has a high water content and a high hardness. The hardness is preferably >=4 kg expressed in terms of penetration hardness measured by a rheometer. The objective product is obtained by condensing a trehalose-containing aqueous solution so as to have 3.5-10 wt.%, preferably >=5 wt.% and <10 wt.% water content. The objective product preferably contains >=65 wt.% trehalose expressed in terms of anhydride based on the whole saccharides. The trehalose-containing aqueous solution preferably has <70 wt.% trehalose concentration. The objective product has high transparency, hardly causes cogging, is capable of allowing an energy consumption required for condensing to be reduced, and is excellent in operability, productivity and yield.
The invention discloses a bacillus subtilis strain for high yield of nattokinase and application thereof, belonging to the technical field of microorganisms. The bacillus subtilis is preserved in the common microorganism center of China general microbiological culture Collection center (CGMCC) at 11 days 12 months 2020, and the preservation address is microbial research institute of China academy of sciences No. 3, North Cheng West Lu No. 1 institute of Chao Yang district, Beijing, and the preservation number is CGMCC No. 21354. The strain has the characteristics of simple nutritional conditions, easy culture and the like. When the nattokinase is used for fermentation production of nattokinase, the level of the nattokinase produced is obviously improved, and the enzyme activity of the obtained nattokinase is about 23000 IU/mL. When the natto kinase liquid is applied to the bean milk fermented by the mixed liquid of beans and grains, the volatile basic nitrogen is obviously reduced while the activity of the natto kinase is kept, and the odor is better. In addition, when the method is applied to the compounding of beans and grains for solid fermentation, the enzyme activity of the nattokinase in a fermented product can reach 30000 IU/g.
The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.
Electrical stimulation utilized to generate SEPs, performed pre and post LIFU application. One of three LIFU pressures will be applied. One per study visit (3), randomized order. EEG collected throughout visit (outcome measure).
A polymer having a molecular weight less than 6000 which is soluble in water at basic pH values and having the formula <FORM:1002455/C3/1> where R is a C2- 4 alkylene radical which may contain as substituent a C1- 4 alkyl, carboxyl or carbalkoxy group; R1 is H or a C1- 4 alkyl, and R11 and R111 are R1, aryl, aryloxy or a C1- 4 alkoxy, and n is 1-24 is prepared by reacting a copolymer containing <FORM:1002455/C3/2> with an aminothiol of formula HS-R-NHR1, where R and R1 are as before.  The polymer may be produced by copolymerizing maleic anhydride with styrene or ethylene and then reacting the copolymer with b -mercapto-ethylamine or cysteine. The thiolated polymer, e.g. 1-20%, may be compounded with urea, ammonia, and water.ALSO:Keratinic fibres are impregnated with a solution e.g. 1-20%, of a polymer of molecular weight less than 6,000 which is soluble in water at baric pH values and which has the formula <FORM:1002455/D1-D2/1> where R is a C2-4 alkylene which may be substituted, R1 is H or a C1-4 alkyl and R11 and R111 are R1, aryl, arylotz or C1-4 alkoxy and n is 1-24. The solution may also contain urea and ammonia.  The fibre may be wool or natural hair on the human head and may be constrained during treatment to a desired configuration.
The invention discloses a false tooth material composition. The false tooth material composition comprises, by weight, 95-105 parts of a dentistry special-purpose tooth-making liquid, 95-105 parts of heat setting denture acrylic powder, 0.10-0.15 parts of an anticracking agent, 0.5-0.8 parts of a plasticizer and 0.1-0.3 parts of a tooth-making pigment. The dentistry special-purpose tooth-making liquid is a methyl methacrylate monomer. The heat setting denture acrylic powder is polymethyl methacrylate. The anticracking agent is polysulfone resin. The plasticizer is a mixture of benzyl salicylate and ethanol or a mixture of dibutyl phthalate and ethanol. The tooth-making pigment is zinc oxide. The polysulfone resin in the composition is used for solving the problem of easy cracking of an acrylic acid polymer material. Zinc oxide is used as the tooth-making pigment. Through control of different use amounts, false teeth has a plurality of colors, satisfy requirements on matching of dermal teeth and false teeth of a dental patent and personal tooth color appetite, and has a low price and good adaptability.
Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14) affecting 26% of colorectal cancers and a smaller fraction of lung, breast and gastric cancers. Fifteen mutations were nonsense, frameshift or splice site alterations predicted to result in truncated proteins lacking phosphatase activity. Five missense mutations in the most commonly altered PTP (PTPRP) were biochemically examined and found to reduce phosphatase activity. Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth. These observations suggest that the tyrosine phosphatase genes are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.
PURPOSE: To optain a new physiologically active substance useful as an contraceptive and an anti-cancer agent. CONSTITUTION: This PF1092A is a substance shown by the formula or its salt. Color and shape: colorless needle-like crystal. Molecular formula: C17 H20 O5 . Mass spectrum (FD-MS); m/z-304 (M)<+> . Specific rotation: [α]<24> D=-10.86 deg. (C=0.5, CHCl3 ). Solubility: soluble in chloroform, acetone, ethyl acetate, methanol and DMF and insoluble in water and hexane. Distinction of basicity, acidity and neutrality: a neutral substance. Rf value by silica gel thin layer chromatography: 0.25 by a developing solvent of hexane-ethyl acetate (1:1). The substance of the formula is obtained by culturing a fungus PF1092 strain belonging to Penicillium of a filamentous fungus under aerobic conditions, extracting the culture product with a solvent and purifying and separating the substance by silica gel column chromatography.  The substance has inhibitory action on bonding of progesterone to a progesterone acceptor and is useful as an oral anticonceptive and a therapeutic agent for mastocarcinoma.
Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
(1) Background: The Modified Ashworth Scale (MAS) is commonly used clinically to evaluate spasticity, but its qualitative nature introduces subjectivity. We propose a novel metric scale to quantitatively measure spasticity using mechanomyography (MMG) to mitigate these subjective effects. (2) Methods: The flexor and extensor muscles of knee and elbow joints were assessed with the Modified Ashworth Scale (MAS) during the acquisition of mechanomyography (MMG) data. The median absolute amplitude of the MMG signals was utilized as a key descriptor. An algorithm was developed to normalize the MMG signals to a universal gravitational (G) acceleration scale, aligning them with the limits and range of MAS. (3) Results: We evaluated 34 lower and upper limbs from 22 volunteers (average age 39.91 ± 13.77 years) of both genders. Polynomial regression provided the best fit (R2 = 0.987), with negligible differences (mean of 0.001 G) between the MAS and MMG. We established three numerical sets for the median, minimum, and maximum MMG(G) values corresponding to each MAS range, ensuring consistent alignment of the Modified Ashworth levels with our proposed scale. (4) Conclusions: Muscle spasticity can now be quantitatively and semi-automatically evaluated using our algorithm and instrumentation, enhancing the objectivity and reliability of spasticity assessments.
This pooled analysis was performed on data collated from six GSK studies that provide efficacy data supporting the twice-daily use of a dentifrice containing 67% w/w sodium bicarbonate in the management of pre-existing gingivitis, and plaque accumulation. Six studies that were chosen for inclusion in the pooled analysis were single-center, examiner-blind, 2 to 3 treatments, parallel group, stratified and randomized clinical study. In all studies, participants entered the screening period during which eligibility for the study was determined. The participants included male and non-pregnant, non-lactating female subjects at least 18 years of age with pre-existing gingivitis as determined by an appropriately qualified clinical examiner. Participants meeting the inclusion criteria entered an acclimatization period in order to minimize any potential placebo response. Participants were randomized into treatments, parallel group, stratified and randomized clinical studies twice daily at home for 6, 12 and 24 weeks and participants returned to the site. Participants underwent a full OST examination and the recording of any Adverse Events (AEs). Participants then underwent Modified Gingival Index (MGI), Bleeding Index (BI), Gingival Severity Index (GSI) followed by dental plaque assessments.
Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.
These are the cohort of players that consent to the study and have a preseason baseline blood sample taken. If the participant from this cohort then receives a concussion they are assessed by the World Rugby's Head Injury Assessment (HIA) and then enter into the return to play (RTP) protocol which means they cannot play a competitive game for 6 days.
The study population will comprise women with abnormal uterine bleeding who will be scheduled for endometrial sampling or women who will have control biopsies before surgery due to other pathologies. We have two groups; the first group consisted of patients who receive lidocaine spray. The second group consisted of patients who receive placebo spray. Patients will be asked to rate their pain level on a standard continuous 100-mm VAS to quantify the pain. Pain scoring will be performed at 3 different time points: immediately before to the procedure, during the procedure(immediately following the removal of the speculum from the vagina at the end of the endometrial sampling, the patients will be asked to score their pain level experienced during the procedure), and 15 minutes after the procedure.

We will document the patients' demographics and medical information. All procedures will be performed by a single operator and the same team to avoid possible operator-dependent pain factors (counseling, patient preparation, attitude and operative steps during operation, moral and psychological support).
Three randomized, double-blind, vehicle-controlled, multi-center, Phase 3 trials were conducted in 589 pediatric subjects ages 3 months-17 years old to evaluate pimecrolimus cream, 1% for the treatment of mild to moderate atopic dermatitis. Two of the three trials support the use of pimecrolimus cream, 1% in subjects 2 years and older with mild to moderate atopic dermatitis [see Warnings and Precautions (5.1)]. Three other trials in 1,619 pediatric and adult subjects provided additional data regarding the safety of pimecrolimus cream, 1% in the treatment of atopic dermatitis. Two of these other trials were vehicle-controlled with optional sequential use of a medium potency topical corticosteroid in pediatric subjects and one trial was an active comparator trial in adult subjects with atopic dermatitis [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

Two identical 6-week, randomized, vehicle-controlled, multi-center, Phase 3 trials were conducted to evaluate pimecrolimus cream, 1% for the treatment of mild to moderate atopic dermatitis. A total of 403 pediatric subjects 2 to 17 years old were included in the trials. The male/female ratio was approximately 50% and 29% of the subjects were African American. At trial entry, 59% of subjects had moderate disease and the mean body surface area (BSA) affected was 26%. About 75% of subjects had atopic dermatitis affecting the face and/or neck region. In these trials, subjects applied either pimecrolimus cream, 1% or vehicle cream twice daily to 5% to 96% of their BSA for up to 6 weeks. At endpoint, based on the physician’s global evaluation of clinical response, 35% of subjects treated with pimecrolimus cream, 1% were clear or almost clear of signs of atopic dermatitis compared to only 18% of vehicle-treated subjects. More pimecrolimus subjects (57%) had mild or no pruritus at 6 weeks compared to vehicle subjects (34%). The improvement in pruritus occurred in conjunction with the improvement of the subjects’ atopic dermatitis.

In these two 6-week trials of pimecrolimus, the combined efficacy results at endpoint are presented in Table 2 as follows:

Table 2. Combined Efficacy Results at Endpoint for Two 6-week Trials of Pimecrolimus Cream % Subjects

In the two pediatric trials that independently support the use of pimecrolimus cream, 1% in mild to moderate atopic dermatitis, a significant treatment effect was seen by day 15. Of the key signs of atopic dermatitis, erythema, infiltration/papulation, lichenification, and excoriations were reduced at day 8 when compared to vehicle.

Figure 1 depicts the time course of improvement in the percent body surface area affected as a result of treatment with pimecrolimus cream, 1% in 2 to 17 year olds.

Figure 1

Figure 2 shows the time course of improvement in erythema as a result of treatment with pimecrolimus cream, 1% in 2 to 17 year olds.

Figure 2
For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until \~5h post habitual breakfast time on testing day 7.